VIGANO PAUL R sold $192.6M of AVAH (indirect holdings)

VIGANO PAUL R sold 16,750,002 indirectly-held shares of Aveanna Healthcare Holdings, Inc. (AVAH) at $11.50 ($192.63M total) across 6 trades over 2026-08-20 to 2026-08-21.

Original reporting
SEC EDGAR · VIGANO PAUL R
Published Aug 24, 2026, 10:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 24, 2026, 10:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AVAH
Bearish
medium confidence
Mentioned
$AVAH
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AVAHBearishMed
01

Why it matters

The $192.6M sale reduces insider ownership, potentially signaling concerns about future performance.

02

Market read

AVAH may face short‑term price pressure; traders should monitor volume and price reaction.

03

What to watch

Sale was executed via open market, not a 10b5‑1 plan, indicating possible discretionary motive.

Relevance 8/10Novelty 8/10Timing: Filed 2026-08-24, immediate market impact possible

Background

Form 4 filings disclose insider transactions; large sales by major shareholders attract trader attention.

Company-level read

Ticker impact

$AVAHBearishMedium confidence
Context

Insider Paul VIGANO sold 16.75M shares (~$192.6M) of Aveanna Healthcare, reducing his stake to 12.3M shares.

Expected impact

Potential modest decline in AVAH over the next few days.

Evidence & confidence

Sale size is significant for a mid‑cap; insider is a 10% owner, suggesting possible concerns.

Market effects

Healthcare services sector may see slight pressure as insider activity raises questions.

U.S. healthcare stocks could experience minor pullback.

Limited to investors tracking Aveanna and related healthcare peers.

Counterpoint

Insider may be diversifying; sale does not necessarily reflect company fundamentals.

Key entities

  • Aveanna Healthcare Holdings, Inc.

    Provider of home health and hospice services, ticker AVAH.

  • Paul VIGANO

    10% owner of AVAH who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AVAHHighAI 8/10

Aveanna Healthcare Earnings Call Signals Broader Growth, Higher Guidance

Aveanna Healthcare (AVAH) reported Q3 revenue of $695.5M, up 11.8%, and adjusted EBITDA of $100.1M, up 25%. All segments grew, with Home Health and Hospice up 15.6%, Private Duty Services up 11.6%, and Medical Solutions up 9.1%. The company raised 2026 guidance to revenue above $2.695B and adjusted EBITDA above $374M, citing growth in preferred payers and state rate enhancements. Management highlighted caregiver shortages and California rate uncertainty as risks.

$AVAHMedAI 8/10

What Aveanna Healthcare (AVAH) Said on Its Q3 Earnings Call

Aveanna Healthcare (AVAH) reported Q3 revenue growth of 15.6% to $72.1M in Home Health and Hospice, and 9.1% to $49.2M in Medical Solutions. CEO Shaner cautioned that 20-25% growth is unsustainable. The company secured $30M in California funding for rate increases, aiming for permanency. Aveanna reconfirmed long-term growth targets and plans to focus acquisitions on Home Health and Hospice. It reported $492M in liquidity and $1.52B in variable-rate debt, all hedged through 2029.

$AVAHHigh

Raymond James reiterates Strong Buy on Aveanna stock after beat

Raymond James reiterated a Strong Buy rating and $15.00 price target for Aveanna Healthcare (AVAH) after its Q3 2026 results beat estimates. AVAH reported adjusted EBITDA of $100.1M, 7.5% above consensus, and raised its 2026 EBITDA guidance to at least $374M. The stock trades at $13.09, with 13% upside to the target. RBC Capital increased its price target to $16.00, citing positive market positioning.